Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Director comp.
Quarterly results
TREVENA INC (TRVN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "TREVENA, INC. Condensed Statements of Operations Three Months Ended Jun 30, Six Months Ended Jun 30, 2023 2022 2023 2022 Product revenue $ 21 $ - $ 27 $ - License revenue 3,000 - 3,000 20 Total revenue 3,021 - 3,027 20 Operating expenses: Cost of goods sold 88 216 214 423 Selling, general and administrative 5,138 10,306 11,227 21,320 Research and development 3,991 4,291 7,900 9,550 Total operating expenses 9,217 14,813 19,341 31,293 Loss from operations Other income 483 Net loss $ $ $ $ Per share information: Net loss per share of common stock, basic and diluted $ $ $ $ Weighted average shares outstanding, basic and diluted 11,580,128 6,621,083 10,592,586 6,620,942 TREVENA, INC. Condensed Balance Sheets"
05/15/2023 8-K Quarterly results
Docs: "TREVENA, INC. Condensed Statements of Operations Three Months Ended Mar 31, 2023 2022 Product revenue $ 6 $ - License revenue - 20 Total revenue 6 20 Operating expenses: Cost of goods sold 127 207 Selling, general and administrative 6,089 11,014 Research and development 3,909 5,259 Total operating expenses 10,125 16,480 Loss from operations Other income 2,300 71 Net loss $ $ Per share information: Net loss per share of common stock, basic and diluted $ $ Weighted average shares outstanding, basic and diluted 9,594,072 6,620,800 TREVENA, INC. Condensed Balance Sheets",
"CLIN PHASE 1 PHASE 2 PHASE 3 NDA POST"
11/09/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/13/2020 8-K Quarterly results
11/04/2019 8-K Quarterly results
Docs: "Trevena Reports Third Quarter 2019 Results and Topline Data From Multi-Dose Healthy Volunteer QT Study — — Company expects to resubmit NDA for oliceridine in Q1 2020 — — Acute migraine proof-of-concept study for TRV250 initiated —"
08/07/2019 8-K Quarterly results
05/10/2019 8-K Quarterly results
Docs: "Trevena Reports First Quarter 2019 Results — Company announces receipt of FDA feedback on healthy volunteer study protocol and analysis plan for oliceridine"
03/13/2019 8-K Quarterly results
Docs: "Trevena Reports Fourth Quarter and Full Year 2018 Results — Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA — — Successful fundraising extends cash runway into 3Q 2020 —"
11/08/2018 8-K Quarterly results
Docs: "Trevena Reports Third Quarter 2018 Financial Results and Announces Workforce Restructuring — $70.0 Million of Cash, Cash Equivalents and Marketable Securities as of September 30, 2018 — — Company to host conference call and webcast at 8:00 am EST — CHESTERBROOK, PA, November 8, 2018 — Trevena, Inc. , a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain, today reported third quarter 2018 financial results and announced a workforce restructuring to preserve capital while the Company continues development of oliceridine. As part of this plan, the Company is reducing its workforce by approximately one-third and is undertaking additional cost saving initiatives that in total are expected to save more than $3.5 ..."
08/02/2018 8-K Quarterly results
Docs: "Trevena Reports Second Quarter 2018 Financial Results"
05/03/2018 8-K Quarterly results
Docs: "Trevena Reports First Quarter 2018 Financial Results"
03/07/2018 8-K Quarterly results
Docs: "Trevena Reports Full Year 2017 Earnings"
11/07/2017 8-K Quarterly results
Docs: "Trevena Reports Third Quarter 2017 Financial Results and Announces New Positive Clinical Trial Data"
08/03/2017 8-K Quarterly results
Docs: "Trevena Reports Second Quarter 2017 Financial Results and Provides Corporate Update"
05/04/2017 8-K Form 8-K - Current report
03/08/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/04/2016 8-K Form 8-K - Current report
05/05/2016 8-K Form 8-K - Current report
03/09/2016 8-K Form 8-K - Current report
11/10/2015 8-K Quarterly results
Docs: "Trevena Reports Third Quarter 2015 Financial Results and Provides Corporate Update"
08/11/2015 8-K Quarterly results
Docs: "Trevena Reports Second Quarter 2015 Financial Results and Provides a Corporate Update"
05/07/2015 8-K Quarterly results
Docs: "Trevena Reports First Quarter 2015 Financial Results and Provides a Corporate Update"
03/18/2015 8-K Quarterly results
Docs: "Trevena Reports Full Year 2014 Financial Results"
11/12/2014 8-K Quarterly results
Docs: "Trevena Reports Third Quarter 2014 Financial Results and Provides a Corporate Update"
08/12/2014 8-K Quarterly results
Docs: "TREVENA, INC. Condensed Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2014 2013 2014 2013 Revenue $ — $ 93,779 $ — $ 134,980 Operating expenses: General and administrative 2,475,820 871,275 4,496,685 1,632,712 Research and development 9,031,037 3,494,681 16,664,546 5,609,747 Total operating expenses 11,506,857 4,365,956 21,161,231 7,242,459 Loss from operations Other income 11,176 292,136 Net loss and comprehensive loss Accretion of redeemable convertible preferred stock — Net loss attributable to common stockholders $ $ $ $ Per share information: Net loss per share of common stock, basic and diluted $ $ $ $ Weighted average shares outstanding, basic and diluted 26,327,895 756,083 21,343,803 722,637 TREVENA, INC. Condensed Balance Sheets Assets Current..."
05/09/2014 8-K Quarterly results
Docs: "Trevena Inc. Statement of Operations Three Months Ended March 31, 2013 2014 Revenue: Grant revenue $ 41,201 $ — Collaboration revenue — — Total revenue 41,201 — Operating expenses: General and administrative 761,437 2,020,865 Research and development 2,115,066 7,633,509 Total operating expenses 2,876,503 9,654,374 Loss from operations Other income : Change in fair value of warrant liability 10,255 98,922 Miscellaneous income — 176,015 Interest income — 6,023 Interest expense — Total other income 280,960 Net loss and comprehensive loss Accretion of redeemable convertible preferred stock Net loss attributable to common stockholders $ $ Per share information: Net loss per share of common stock, basic and diluted $ $ Weighted average shares outstanding, basic and diluted 689,266 16,023,497..."
03/20/2014 8-K Quarterly results
Docs: "Trevena Inc. Statement of Operations Year Ended December 31, 2012 2013 Revenue: Grant revenue $ 407,595 $ 84,980 Collaboration revenue 400,000 50,000 Total revenue 807,595 134,980 Operating expenses: General and administrative 3,122,718 4,718,047 Research and development 13,294,917 18,762,219 Total operating expenses 16,417,635 23,480,266 Loss from operations Other income : Change in fair value of warrant liability 44,576 241,478 Miscellaneous income 122,792 1,245 Interest income 754 884 Interest expense Total other income 93,851 Net loss and comprehensive loss Accretion of redeemable convertible preferred stock Net loss attributable to common stockholders $ $ Per share information: Net loss per share of common stock, basic and diluted $ $ Weighted average shares outstanding, basic an..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy